Raymond James initiated coverage of Tyra Biosciences (TYRA) with a Strong Buy rating and $35 price target Tyra’s unique SNAP development platform, as validated with the first discovery candidate, TYRA-300, is “potentially best-in-class,” says the analyst, who sees “multi-billion-dollar revenue potential” in the indications being investigated.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TYRA:
- Tyra Bioscience’s Promising Developments in NMIBC and Achondroplasia Drive Buy Rating
- Tyra Bioscience Begins Phase 2 Study for Achondroplasia
- Tyra Biosciences says first child dosed in BEACH301 trial
- Tyra Bioscience: Strategic Advancements and Financial Stability Justify Buy Rating
- Tyra Bioscience: Promising Clinical Trials and Financial Stability Justify Buy Rating